| Literature DB >> 35116224 |
Kun Zhao1,2,3, Ya Wen1,3, Varitsara Bunpetch1,3, Junxin Lin1,3, Yejun Hu1,3, Xiaoan Zhang1,3, Yuan Xie1,3, Shufang Zhang1,3,4, Ouyang Hongwei1,2,3,4.
Abstract
BACKGROUND: Intra-articular injections of hyaluronic acid (HA), the United States Food and Drug Administration approved treatment and widely utilized to delay or reserve the progression of the osteoarthritis (OA) involves. However, this treatment has shown controversial results through various clinical practice guidelines and meta-analysis evaluations, warrants more advanced researches on its safety and effectiveness.Entities:
Keywords: Hyaluronic acid; Meta-analysis; Multi-organ transcriptomics; Osteoarthritis; Randomized controlled clinical trails
Year: 2022 PMID: 35116224 PMCID: PMC8777245 DOI: 10.1016/j.jot.2021.11.006
Source DB: PubMed Journal: J Orthop Translat ISSN: 2214-031X Impact factor: 5.191
Fig. 1Meta-analysis of intra-articular injected HA (A) literature search and screening process (B) risk of bias of included trials (C). Sensitivity analysis of short-term result for HA compared to saline (D) Sensitivity analysis of long-term result for HA compared to saline (E). Adverse events results for HA compared to saline.
Characterize of included studies.
| Trial | No. of Patients | Intervention | Outcome | Measurement timepoint from baseline | ||
|---|---|---|---|---|---|---|
| HA | Saline | HA Type | Average Molecular Weight, kDa | |||
| Dougados,1993 | 55 | 55 | Hyalgan | 500–730 | Pain: VAS | 7w, 52w |
| Altman,1998 | 105 | 115 | Hyalgan | 500–730 | Pain: VAS | 9w, 12w, 16w, 21w,26w |
| Huskisson,1999 | 50 | 50 | Hyalgan | 500–730 | Pain: VASFunction: Lequesne's index | 2 m, 4 m, 6 m |
| Karlsson,2002 | 90 | 66 | Artzal | 500–1000 | Pain: VAS | 20w, 26w |
| Altman,2004 | 172 | 174 | Durolane | Unclear | Pain:WOMAC pain | 6w, 13w, 26w |
| Pham,2004 | 131 | 85 | NRD101 | 1900 | Pain: VAS | 52w |
| Cubukcu,2005 | 30 | 10 | Hylan G-F 20 | 6000 | Pain: VAS, WOMAC pain | 8w |
| Petrella,2006 | 53 | 53 | Unclear | Unclear | Pain: VAS, WOMAC pain | 6w |
| Altman,2009 | 291 | 295 | Euflexxa | 2400–3600 | Pain: VAS | 26w |
| Chevalier,2010 | 124 | 129 | Hylan G-F 20 | 6000 | Pain: WOMAC pain | 26w |
| Kul-Panza,2010 | 25 | 23 | Orthovisc | 1500 | Pain: VAS, WOMAC pain | 14w |
| Huang,2011 | 100 | 98 | Hyalgan | 500–730 | Pain: VAS, WOMAC pain | 13, 25w |
| Arden,2014 | 108 | 110 | Durolane | Unclear | Pain: WOMAC pain | 6w |
| Bao,2018 | 20 | 20 | ARTZ | 620–1170 | Pain: VAS, WOMAC pain | 8w |
| Hangody,2018 | 150 | 69 | Monovisc | Unclear | Pain: WOMAC pain | 6w, 12w, 18w, 26w |
| Petterson,2018 | 181 | 184 | Monovisc | Unclear | Pain: VAS | 8w, 12w, 20w, 26w |
Fig. 2The effects of HA on chondrocytes (A) A heatmap of differentially expressed mRNA levels from RNA-seq analysis performed on chondrocytes cultured on HA-coated plates (B) Gene Ontology (GO) enrichment and KEGG analysis of the upregulated genes in chondrocytes (C) Chondrocyte- and inflammation-related genes (Col2a1, Acan, Sox9, Mmp13), and the (D) ELISA analysis of IL-1β and TNFα cytokine productions by macrophages cultured on HA-coated dishes (E) A heatmap of DEGs from RNA-seq performed on intra-articular HA-injected knee joints, as well as the (F) GO and KEGG analysis (G) Histological sections of the HA-injected knee joints at 1-week post-operation. Original magnification x20; scale bar: 50um (H) ICRS scoring on cartilage.
Fig. 3Systemic influence of intra-articular injected HA on tissue specific gene expression (A) A flow diagram of the study: lymph node, spleen, kidney, and liver were collected after treatment (B) Heapmaps illustrating DEGs of all four tissues compared with control (C) GO analysis of the relevant upregulated genes in different organs in intra-articular HA-injected mice.
Fig. 4Histological evaluation of post-HA injection and OA model, including the (A) lymph node (magnification x20; scale bar: 50um), (B) spleen (magnification x10; scale bar: 100um), (C) kidney (magnification x40; scale bar: 50um), (D) and liver (magnification x40; scale bar: 50um). Quantitative evaluations of the white pulp and germinal center areas in (E) lymph node and (F) spleen (ratio%), (G) Histological sections of the HA-injected knee joints in OA model. Original magnification x20; scale bar: 50um, (H) ICRS scoring on cartilage.